{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:16Z","timestamp":1772165656710,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Few data are available regarding the use of direct antiviral agents (DAAs) for chronic hepatitis C in psychiatric patients. The aim of the study is to assess safety and outcome of DAAs in patients with psychiatric comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, observational, single-centre study enrolled patients treated with psychiatric drugs who initiated DAAs between 2015 and 2018. Patients were classified into two groups: A (on anxiolitycs\/antidepressant) and B (on antipsychotics). Week-12 sustained virological response (SVR-12) and adverse events (AEs) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred forty-four patients were included (A:101; B:43). Patients were 49.3% males, mean age 60\u2009years (SD\u2009\u00b1\u200913.5); 31.9% cirrhotic; 125 (86.8%) HCV-monoinfected and 19 (13.2%) HCV \/HIV-coinfected. Twenty patients (13.8%) required a change of psychiatric therapy before initiation of DAA. Overall, SVR-12 was achieved in 88.2% of subjects in intention-to-treat(ITT)-analysis. Lower SVR rates were observed in group B vs A (79% vs 92%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.045) and in those changing psychiatric drugs vs others (8% vs 30%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.015). According to per-protocol (PP)-analysis, SVR-12 was achieved in 93\/95 (97.9%) in group A versus 34\/36 (94.4%) in group B (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.30). At least one AE occurred in 60 patients (41.6%), including 10 severe AEs, leading to 3 discontinuations. AEs were more frequently reported in group A (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.015).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study confirms effectiveness and safety of DAA-based treatment also in this special population, even if a careful evaluation of history and drug-drug interactions is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-4922-2","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T23:51:33Z","timestamp":1583452293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and tolerability of DAAs in HCV-monoinfected and HCV\/HIV-coinfected patients with psychiatric disorders"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0731-4590","authenticated-orcid":false,"given":"Nicol\u00f2","family":"de Gennaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Diella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Monno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gioacchino","family":"Angarano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"4922_CR1","volume-title":"GLOBAL HEPATITIS REPORT","author":"WHO","year":"2017","unstructured":"WHO. GLOBAL HEPATITIS REPORT 2017. https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/ Accessed 10 Aug 2019."},{"key":"4922_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/1743-422X-8-346","volume":"8","author":"D Revie","year":"2011","unstructured":"Revie D, Salahuddin SZ. Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence. Virol J. 2011 Jul 11;8:346.","journal-title":"Virol J"},{"key":"4922_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cld.2008.03.012","volume":"12","author":"AL Zignego","year":"2008","unstructured":"Zignego AL, Crax\u00ec A. A Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis. 2008;12:611\u201336.","journal-title":"Clin Liver Dis"},{"key":"4922_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jhep.2012.07.037","volume":"57","author":"M Schaefer","year":"2012","unstructured":"Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012;57:1379\u201390.","journal-title":"J Hepatol"},{"key":"4922_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11894-002-0041-z","volume":"4","author":"LM Martin","year":"2002","unstructured":"Martin LM, Sheridan MJ, Younossi ZM. The impact of liver disease on health-related quality of life: a review of the literature. Curr Gastroenterol Rep. 2002;4:79\u201383.","journal-title":"Curr Gastroenterol Rep"},{"key":"4922_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jare.2016.09.005","volume":"8","author":"L Yarlott","year":"2017","unstructured":"Yarlott L, Heald E, Forton D. Hepatitis C virus infection, and neurological and psychiatric disorders \u2013 a review. J Adv Res. 2017;8:139\u201348.","journal-title":"J Adv Res"},{"key":"4922_CR7","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.3748\/wjg.v21.i8.2269","volume":"21","author":"LE Adinolfi","year":"2015","unstructured":"Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, et al. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol. 2015;21:2269\u201380.","journal-title":"World J Gastroenterol"},{"key":"4922_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/10398560701358113","volume":"15","author":"C Lacey","year":"2007","unstructured":"Lacey C, Ellen S, Devlin H, Wright E, Mijch A. Hepatitis C in psychiatry inpatients: testing rates, prevalence and risk behaviours. Australas Psychiatry. 2007;15:315\u20139.","journal-title":"Australas Psychiatry"},{"key":"4922_CR9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.1440-1819.2000.00754.x","volume":"54","author":"S Hosoda","year":"2000","unstructured":"Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci. 2000;54:565\u201372.","journal-title":"Psychiatry Clin Neurosci"},{"key":"4922_CR10","doi-asserted-by":"publisher","first-page":"e107592","DOI":"10.1371\/journal.pone.0107592","volume":"9","author":"C Niederau","year":"2014","unstructured":"Niederau C, Mauss S, Schober A, Stoehr A, Zimmermann T, Waizmann M, et al. Predictive factors for sustained virological response after treatment with pegylated interferon \u03b1-2a and ribavirin in patients infected with HCV genotypes 2 and 3. PLoS One. 2014;9:e107592.","journal-title":"PLoS One"},{"key":"4922_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461\u2013511.","journal-title":"J Hepatol"},{"key":"4922_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/hep.30171","volume":"69","author":"MK Jain","year":"2019","unstructured":"Jain MK, Thamer M, Therapondos G, Shiffman ML, Kshirsagar O, Clark C. Has access to hepatitis C virus therapy changed for patients with mental health or substance use disorders in the direct-acting-antiviral period? Hepatology. 2019;69:51\u201363.","journal-title":"Hepatology"},{"key":"4922_CR13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jvh.13110","volume":"26","author":"D Back","year":"2019","unstructured":"Back D, Belperio P, Bondin M, Negro F, Talal AH, Park C, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: an integrated analysis. J Viral Hepat. 2019;26:951\u201360.","journal-title":"J Viral Hepat"},{"issue":"5","key":"4922_CR14","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/add.14128","volume":"113","author":"S Christensen","year":"2018","unstructured":"Christensen S, Buggisch P, Mauss S, B\u00f6ker K, Schott E, Klinker H, et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice? Addiction. 2018;113(5):868\u201382.","journal-title":"Addiction"},{"key":"4922_CR15","first-page":"1","volume":"0","author":"M Miarons","year":"2018","unstructured":"Miarons M, S\u00e1nchez-Ulayar A, Sempere G, Mar\u00edn S, Castellv\u00ed JM. New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups. Eur J Hosp Pharm. 2018;0:1\u20136.","journal-title":"Eur J Hosp Pharm"},{"key":"4922_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502514","volume":"6","author":"V Gayam","year":"2019","unstructured":"Gayam V, Jegede O, Tiongson B, Mandal AK, Sidhu J, Garlapati P. Outcomes of direct-acting antiviral treatment of psychiatric patients with comorbid hepatitis C virus infection. Dig Dis. 2019;6:1\u20138.","journal-title":"Dig Dis"},{"key":"4922_CR17","unstructured":"EASL. Recommendations on Treatment of Hepatitis C 2015\u20132018. https:\/\/easl.eu\/publications\/clinical-practice-guidelines Accessed 11 Aug 2019."},{"key":"4922_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","volume":"67","author":"JV Lazarus","year":"2017","unstructured":"Lazarus JV, Wictor SZ, Colombo M, Thursz M, EASL International Liver Foundation. Micro-elimination \u2013 a path to global elimination of hepatitis C. J Hepatol. 2017;67:665\u20136.","journal-title":"J Hepatol"},{"key":"4922_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2147\/PPA.S30339","volume":"8","author":"D Larrey","year":"2014","unstructured":"Larrey D, Ripault MP, Pageaux GP. Patient adherence issues in the treatment of hepatitis C. Patient Prefer Adherence. 2014;8:763\u201373.","journal-title":"Patient Prefer Adherence"},{"key":"4922_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/jvh.12674","volume":"24","author":"M Dirks","year":"2017","unstructured":"Dirks M, Pflugrad H, Haag K. Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus? J Viral Hepat. 2017;24:541\u201350.","journal-title":"J Viral Hepat"},{"key":"4922_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1176\/appi.psy.42.5.411","volume":"42","author":"SP Yovtcheva","year":"2001","unstructured":"Yovtcheva SP, Rifai MA, Moles JK, Van der Linden BJ. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics. 2001;42:411\u20135.","journal-title":"Psychosomatics"},{"key":"4922_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1053\/gast.2002.34750","volume":"123","author":"HB El Serag","year":"2002","unstructured":"El Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123:476\u201382.","journal-title":"Gastroenterology"},{"key":"4922_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jad.2012.03.020","volume":"141","author":"MG Carta","year":"2012","unstructured":"Carta MG, Angst J, Moro MF, Mura G, Hardoy MC, Balestrieri C, et al. Association of chronic hepatitis C with recurrent brief depression. J Affect Disord. 2012;141:361\u20136.","journal-title":"J Affect Disord"},{"key":"4922_CR24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/jgh.12515","volume":"29","author":"JY Wu","year":"2014","unstructured":"Wu JY, Shabolt B, Teoh N, Blunn A, To C, Rodriguez-Morales I, et al. Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C. J Gastroenterol Hepatol. 2014;29:1258\u201364.","journal-title":"J Gastroenterol Hepatol"},{"key":"4922_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12888-018-1735-6","volume":"18","author":"I Sundberg","year":"2018","unstructured":"Sundberg I, Lannerg\u00e5rd A, Ramklint M, Cunningham JL. Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. BMC Psychiatry. 2018;18:157.","journal-title":"BMC Psychiatry"},{"key":"4922_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijid.2017.07.001","volume":"62","author":"G Bruno","year":"2017","unstructured":"Bruno G, Saracino A, Scudeller L, Fabrizio C, Dell'Acqua R, Milano E, et al. HCV mono-infected and HIV\/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Int J Infect Dis. 2017;62:64\u201371.","journal-title":"Int J Infect Dis"},{"key":"4922_CR27","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1001\/jama.2018.6741","volume":"319","author":"DM Quato","year":"2018","unstructured":"Quato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA. 2018;319:2289\u201398.","journal-title":"JAMA."},{"key":"4922_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3851\/IMP3245","volume":"23","author":"D Forton","year":"2018","unstructured":"Forton D, Weissenborn K, Bondin M, Cacoub P. Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations. Antivir Ther. 2018;23:47\u201355.","journal-title":"Antivir Ther"},{"key":"4922_CR29","doi-asserted-by":"publisher","first-page":"e0208112","DOI":"10.1371\/journal.pone.0208112","volume":"13","author":"M Gallach","year":"2018","unstructured":"Gallach M, Vergara M, da Costa JP, Miquel M, Casas M, Sanchez-Delgado J, et al. Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis. PLoS ONE. 2018;13:e0208112.","journal-title":"PLoS ONE"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4922-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-4922-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4922-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T19:23:03Z","timestamp":1614972183000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-4922-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4922"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-4922-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.14807\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14807\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14807\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14807\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"assertion":[{"value":"12 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study did not require approval from the ethics committee, according to the Italian law, since it was performed in the context of normal clinical routines (art.1, leg. Decree 211\/2003). However, all patients referring to our institute provided a written consent at the time of first visit for the use of their data for research purposes. Patients were recruited retrospectively according to General Authorization to process personal data for research purposes (leg. Decree 9\/2016). Data were previously anonymized, according to the requirements set by Italian Data protection Code (leg. Decree 196\/2003).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}